BRIEF-Ocular Therapeutix™ Investor Day To Highlight US FDA Alignment On Axpaxli™ NDA With Submission Planned For Fourth Quarter 2026

Ocular Therapeutix Inc

OCUL

0.00

June 17 (Reuters) - Ocular Therapeutix Inc OCUL.O:

OCULAR THERAPEUTIX™ INVESTOR DAY TO HIGHLIGHT U.S. FDA ALIGNMENT ON AXPAXLI™ NDA WITH SUBMISSION PLANNED FOR FOURTH QUARTER 2026
OCULAR THERAPEUTIX INC - SOL-R EFFICACY DATA NO LONGER PART OF AXPAXLI NDA SUBMISSION PLAN
OCULAR THERAPEUTIX - SOL-R TRIAL TO REMAIN MASKED THROUGH WEEK 96; TOPLINE RESULTS EXPECTED Q1 2028
OCULAR THERAPEUTIX - TO CONDUCT INTERIM SOL-R SAFETY ANALYSIS IN Q4 2026
OCULAR THERAPEUTIX INC - PLANS TO SUBMIT ITS NDA UNDER 505(B)(2) PATHWAY, WITH POTENTIAL TO ACCELERATE REVIEW TIMELINE BY UP TO 60 DAYS

Source text: ID:nGNXfjxfr

Further company coverage: OCUL.O

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.